257 related articles for article (PubMed ID: 18551037)
1. Pharmacogenetics of P450 oxidoreductase: effect of sequence variants on activities of CYP1A2 and CYP2C19.
Agrawal V; Huang N; Miller WL
Pharmacogenet Genomics; 2008 Jul; 18(7):569-76. PubMed ID: 18551037
[TBL] [Abstract][Full Text] [Related]
2. Effects of genetic variants of human P450 oxidoreductase on catalysis by CYP2D6 in vitro.
Sandee D; Morrissey K; Agrawal V; Tam HK; Kramer MA; Tracy TS; Giacomini KM; Miller WL
Pharmacogenet Genomics; 2010 Nov; 20(11):677-86. PubMed ID: 20940534
[TBL] [Abstract][Full Text] [Related]
3. Effect of P450 oxidoreductase variants on the metabolism of model substrates mediated by CYP2C9.1, CYP2C9.2, and CYP2C9.3.
Subramanian M; Agrawal V; Sandee D; Tam HK; Miller WL; Tracy TS
Pharmacogenet Genomics; 2012 Aug; 22(8):590-7. PubMed ID: 22547083
[TBL] [Abstract][Full Text] [Related]
4. Consequences of POR mutations and polymorphisms.
Miller WL; Agrawal V; Sandee D; Tee MK; Huang N; Choi JH; Morrissey K; Giacomini KM
Mol Cell Endocrinol; 2011 Apr; 336(1-2):174-9. PubMed ID: 21070833
[TBL] [Abstract][Full Text] [Related]
5. Genetic variation in human P450 oxidoreductase.
Miller WL; Huang N; Agrawal V; Giacomini KM
Mol Cell Endocrinol; 2009 Mar; 300(1-2):180-4. PubMed ID: 18930113
[TBL] [Abstract][Full Text] [Related]
6. Characterization of Interactions Among CYP1A2, CYP2B4, and NADPH-cytochrome P450 Reductase: Identification of Specific Protein Complexes.
Connick JP; Reed JR; Backes WL
Drug Metab Dispos; 2018 Mar; 46(3):197-203. PubMed ID: 29233819
[TBL] [Abstract][Full Text] [Related]
7. Electron transfer by human wild-type and A287P mutant P450 oxidoreductase assessed by transient kinetics: functional basis of P450 oxidoreductase deficiency.
Jin Y; Chen M; Penning TM; Miller WL
Biochem J; 2015 May; 468(1):25-31. PubMed ID: 25728647
[TBL] [Abstract][Full Text] [Related]
8. P450 oxidoreductase deficiency: a disorder of steroidogenesis with multiple clinical manifestations.
Miller WL
Sci Signal; 2012 Oct; 5(247):pt11. PubMed ID: 23092891
[TBL] [Abstract][Full Text] [Related]
9. Variability in human drug metabolizing cytochrome P450 CYP2C9, CYP2C19 and CYP3A5 activities caused by genetic variations in cytochrome P450 oxidoreductase.
Velazquez MNR; Parween S; Udhane SS; Pandey AV
Biochem Biophys Res Commun; 2019 Jul; 515(1):133-138. PubMed ID: 31128914
[TBL] [Abstract][Full Text] [Related]
10. Substrate-specific modulation of CYP3A4 activity by genetic variants of cytochrome P450 oxidoreductase.
Agrawal V; Choi JH; Giacomini KM; Miller WL
Pharmacogenet Genomics; 2010 Oct; 20(10):611-8. PubMed ID: 20697309
[TBL] [Abstract][Full Text] [Related]
11. Impaired hepatic drug and steroid metabolism in congenital adrenal hyperplasia due to P450 oxidoreductase deficiency.
Tomalik-Scharte D; Maiter D; Kirchheiner J; Ivison HE; Fuhr U; Arlt W
Eur J Endocrinol; 2010 Dec; 163(6):919-24. PubMed ID: 20844025
[TBL] [Abstract][Full Text] [Related]
12. Polymorphisms in cytochrome P450 oxidoreductase and its effect on drug metabolism and efficacy.
Gong L; Zhang CM; Lv JF; Zhou HH; Fan L
Pharmacogenet Genomics; 2017 Sep; 27(9):337-346. PubMed ID: 28731962
[TBL] [Abstract][Full Text] [Related]
13. P450 Oxidoreductase deficiency: Analysis of mutations and polymorphisms.
Burkhard FZ; Parween S; Udhane SS; Flück CE; Pandey AV
J Steroid Biochem Mol Biol; 2017 Jan; 165(Pt A):38-50. PubMed ID: 27068427
[TBL] [Abstract][Full Text] [Related]
14. Impairment of human CYP1A2-mediated xenobiotic metabolism by Antley-Bixler syndrome variants of cytochrome P450 oxidoreductase.
Kranendonk M; Marohnic CC; Panda SP; Duarte MP; Oliveira JS; Masters BS; Rueff J
Arch Biochem Biophys; 2008 Jul; 475(2):93-9. PubMed ID: 18455494
[TBL] [Abstract][Full Text] [Related]
15. Clinical, structural and functional implications of mutations and polymorphisms in human NADPH P450 oxidoreductase.
Flück CE; Nicolo C; Pandey AV
Fundam Clin Pharmacol; 2007 Aug; 21(4):399-410. PubMed ID: 17635179
[TBL] [Abstract][Full Text] [Related]
16. Human cytochrome P450 oxidoreductase deficiency caused by the Y181D mutation: molecular consequences and rescue of defect.
Marohnic CC; Panda SP; McCammon K; Rueff J; Masters BS; Kranendonk M
Drug Metab Dispos; 2010 Feb; 38(2):332-40. PubMed ID: 19884324
[TBL] [Abstract][Full Text] [Related]
17. P450 oxidoreductase: genetic polymorphisms and implications for drug metabolism and toxicity.
Hart SN; Zhong XB
Expert Opin Drug Metab Toxicol; 2008 Apr; 4(4):439-52. PubMed ID: 18433346
[TBL] [Abstract][Full Text] [Related]
18. Reduction in hepatic drug metabolizing CYP3A4 activities caused by P450 oxidoreductase mutations identified in patients with disordered steroid metabolism.
Flück CE; Mullis PE; Pandey AV
Biochem Biophys Res Commun; 2010 Oct; 401(1):149-53. PubMed ID: 20849814
[TBL] [Abstract][Full Text] [Related]
19. Escherichia coli MTC, a human NADPH P450 reductase competent mutagenicity tester strain for the expression of human cytochrome P450 isoforms 1A1, 1A2, 2A6, 3A4, or 3A5: catalytic activities and mutagenicity studies.
Kranendonk M; Carreira F; Theisen P; Laires A; Fisher CW; Rueff J; Estabrook RW; Vermeulen NP
Mutat Res; 1999 Apr; 441(1):73-83. PubMed ID: 10224324
[TBL] [Abstract][Full Text] [Related]
20. Effect of histidine-tag and R457H and E580Q mutations on catalytic activity of recombinant human cytochrome P450 oxidoreductase.
Niwa T; Minami K; Katagiri M
Drug Metab Pharmacokinet; 2012; 27(1):150-4. PubMed ID: 22123124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]